Human viruses and cancer

Viruses

Volumn 6, Issue 10, 2014, Pages 4047-4079

  Morales Sánchez, Abigail ^a,b   Fuentes Pananá, Ezequiel M ^a  

^a HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Human oncogenic viruses; Infectious cancer; Transforming mechanisms

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; GENOMIC DNA; PROTEIN P53; VIRUS RNA;

APOPTOSIS; BORRELIA BURGDORFERI; BURKITT LYMPHOMA; CAMPYLOBACTER JEJUNI; CANCER RISK; CELL POLARITY; CELL PROLIFERATION; CELL TRANSFORMATION; CHLAMYDOPHILA PSITTACI; CHRONIC INFLAMMATION; DNA REPAIR; EPSTEIN BARR VIRUS; GENOMIC INSTABILITY; HELICOBACTER PYLORI; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HERPES VIRUS; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 8; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNE RESPONSE; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LYMPHOCYTE PROLIFERATION; MERKEL CELL POLYOMAVIRUS; MUTATION; NEOPLASM; NONHUMAN; PERSISTENT VIRUS INFECTION; RETROVIRUS; REVIEW; SURVIVAL; TELOMERE SHORTENING; TUMOR GROWTH; TUMOR VIRUS; VIRUS CARCINOGENESIS; VIRUS CELL INTERACTION; WART VIRUS; IMMUNOLOGICAL TOLERANCE; PHYSIOLOGY; VIROLOGY; VIRUS INFECTION;

APOPTOSIS; CELL TRANSFORMATION, NEOPLASTIC; GENOMIC INSTABILITY; HUMANS; IMMUNE TOLERANCE; NEOPLASMS; ONCOGENIC VIRUSES; TUMOR VIRUS INFECTIONS;

EID: 84908235935     PISSN: 19994915     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v6104047     Document Type: Review

References (205)

1. Rous, P. A transmissible avian neoplasm. (sarcoma of the common fowl.). J. Exp. Med. 1910, 12, 696-705.
2. Rous, P. A sarcoma of the fowl transmissible by an agent separable from the tumor cells. J. Exp. Med. 1911, 13, 397-411.
3. Ellerman, V.; Bang, O. Experimentelle leukämie bei hühnern. Zent. Bakteriol. Parasitenkd. Infectionskr. Hyg. Abt. Orig. 1908, 46, 595-609.
4. Epstein, M.A.; Achong, B.G.; Barr, Y.M. Virus particles in cultured lymphoblasts from burkitt’s lymphoma. Lancet 1964, 1, 702-703.
5. Durst, M.; Gissmann, L.; Ikenberg, H.; zurHausen, H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc. Natl. Acad. Sci. USA 1983, 80, 3812-3815.
6. Boshart, M.; Gissmann, L.; Ikenberg, H.; Kleinheinz, A.; Scheurlen, W.; zur Hausen, H. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J. 1984, 3, 1151-1157.
7. Moore, P.S.; Chang, Y. Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat. Rev. Cancer 2010, 10, 878-889.
8. Parkin, D.M. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 2006, 118, 3030-3044.
9. Koch, R. Untersuchungen über bakterien: V. Die ätiologie der milzbrand-krankheit, begründet auf die entwicklungsgeschichte des bacillus anthracis [investigations into bacteria: V. The etiology of anthrax, based on the ontogenesis of bacillus anthracis]. Cohns Beitr. Biol. Pflanz. 1876, 2, 277-310.
10. Hill, A.B. The environment and disease: Association or causation? Proc. Royal Soc.Med. 1965, 58, 295-300.
11. Thompson, M.P.; Kurzrock, R. Epstein-barr virus and cancer. Clin. Cancer Res. 2004, 10, 803-821.
12. Kulwichit, W.; Edwards, R.H.; Davenport, E.M.; Baskar, J.F.; Godfrey, V.; Raab-Traub, N. Expression of the epstein-barr virus latent membrane protein 1 induces b cell lymphoma in transgenic mice. Proc. Natl. Acad. Sci. USA 1998, 95, 11963-11968.
13. Loeb, L.A.; Springgate, C.F.; Battula, N. Errors in DNA replication as a basis of malignant changes. Cancer Res. 1974, 34, 2311-2321.
14. Prindle, M.J.; Fox, E.J.; Loeb, L.A. The mutator phenotype in cancer: Molecular mechanisms and targeting strategies. Curr. Drug Targets 2010, 11, 1296-1303.
15. Coleman, W.B. Mechanisms of human hepatocarcinogenesis. Curr. Mol. Med. 2003, 3, 573-588.
16. Zucman-Rossi, J.; Laurent-Puig, P. Genetic diversity of hepatocellular carcinomas and its potential impact on targeted therapies. Pharmacogenomics 2007, 8, 997-1003.
17. Chadburn, A.; Abdul-Nabi, A.M.; Teruya, B.S.; Lo, A.A. Lymphoid proliferations associated with human immunodeficiency virus infection. Arch. Pathol. Lab. Med. 2013, 137, 360-370.
18. Correa, P.; Piazuelo, M.B. The gastric precancerous cascade. J. Dig. Dis. 2012, 13, 2-9.
19. Hatakeyama, M.; Higashi, H. Helicobacter pylori caga: A new paradigm for bacterial carcinogenesis. Cancer Sci. 2005, 96, 835-843.
20. Chang, Y.; Cesarman, E.; Pessin, M.S.; Lee, F.; Culpepper, J.; Knowles, D.M.; Moore, P.S. Identification of herpesvirus-like DNA sequences in aids-associated kaposi’s sarcoma. Science 1994, 266, 1865-1869.
21. Zur Hausen, H. Papillomaviruses and cancer: From basic studies to clinical application. Nat. Rev. Cancer 2002, 2, 342-350.
22. Feng, H.; Shuda, M.; Chang, Y.; Moore, P.S. Clonal integration of a polyomavirus in human merkel cell carcinoma. Science 2008, 319, 1096-1100.
23. Beasley, R.P.; Hwang, L.Y.; Lin, C.C.; Chien, C.S. Hepatocellular carcinoma and hepatitis b virus. A prospective study of 22,707 men in taiwan. Lancet 1981, 2, 1129-1133.
24. Choo, Q.L.; Kuo, G.; Weiner, A.J.; Overby, L.R.; Bradley, D.W.; Houghton, M. Isolation of a cDNA clone derived from a blood-borne non-a, non-b viral hepatitis genome. Science 1989, 244, 359-362.
25. Poiesz, B.J.; Ruscetti, F.W.; Gazdar, A.F.; Bunn, P.A.; Minna, J.D.; Gallo, R.C. Detection and isolation of type c retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous t-cell lymphoma. Proc. Natl. Acad. Sci. USA 1980, 77, 7415-7419.
26. Rickinson, A.B.; Kieff, E. Epstein-barr virus. In Fields Virology, Lippincott-Raven Publishers: Philadelphia, PA, USA, 1996; Volume 2, pp. 2397-2446.
27. Henle, G.; Henle, W.; Clifford, P.; Diehl, V.; Kafuko, G.W.; Kirya, B.G.; Klein, G.; Morrow, R.H.; Munube, G.M.; Pike, P., et al. Antibodies to epstein-barr virus in burkitt’s lymphoma and control groups. J. Natl. Cancer Inst. 1969, 43, 1147-1157.
28. Gerber, P.; Walsh, J.H.; Rosenblum, E.N.; Purcell, R.H. Association of eb-virus infection with the post-perfusion syndrome. Lancet 1969, 1, 593-595.
29. Hoagland, R.J. The transmission of infectious mononucleosis. Am. J. Med. Sci. 1955, 229, 262-272.
30. Goldberg, G.N.; Fulginiti, V.A.; Ray, C.G.; Ferry, P.; Jones, J.F.; Cross, H.; Minnich, L. In utero epstein-barr virus (infectious mononucleosis) infection. JAMA: J. Am. Med. Assoc. 1981, 246, 1579-1581.
31. Meyohas, M.C.; Marechal, V.; Desire, N.; Bouillie, J.; Frottier, J.; Nicolas, J.C. Study of mother-to-child epstein-barr virus transmission by means of nested pcrs. J. Virol. 1996, 70, 6816-6819.
32. Stock, I. Infectious mononucleosis-A “childhood disease” of great medical concern. Med. Mon. Pharma. 2013, 36, 364-368.
33. Hjalgrim, H. On the aetiology of hodgkin lymphoma. Dan. Med. J. 2012, 59, B4485.
34. Klein, G.; Klein, E.; Kashuba, E. Interaction of epstein-barr virus (ebv) with human blymphocytes. Biochem. Biophys. Res. Commun. 2010, 396, 67-73.
35. Morgan, D.G.; Niederman, J.C.; Miller, G.; Smith, H.W.; Dowaliby, J.M. Site of epstein-barr virus replication in the oropharynx. Lancet 1979, 2, 1154-1157.
36. Shair, K.H.; Schnegg, C.I.; Raab-Traub, N. Ebv latent membrane protein 1 effects on plakoglobin, cell growth, and migration. Cancer Res. 2008, 68, 6997-7005.
37. Caldwell, R.G.; Wilson, J.B.; Anderson, S.J.; Longnecker, R. Epstein-barr virus lmp2a drives b cell development and survival in the absence of normal b cell receptor signals. Immunity 1998, 9, 405-411.
38. Scholle, F.; Bendt, K.M.; Raab-Traub, N. Epstein-barr virus lmp2a transforms epithelial cells, inhibits cell differentiation, and activates akt. J. Virol. 2000, 74, 10681-10689.
39. Yates, J.L.; Warren, N.; Sugden, B. Stable replication of plasmids derived from epstein-barr virus in various mammalian cells. Nature 1985, 313, 812-815.
40. Dukers, N.H.; Rezza, G. Human herpesvirus 8 epidemiology: What we do and do not know. Aids 2003, 17, 1717-1730.
41. Cai, Q.; Verma, S.C.; Lu, J.; Robertson, E.S. Molecular biology of kaposi’s sarcoma-associated herpesvirus and related oncogenesis. Adv. Virus Res. 2010, 78, 87-142.
42. Viejo-Borbolla, A.; Ottinger, M.; Schulz, T.F. Human herpesvirus 8: Biology and role in the pathogenesis of kaposi’s sarcoma and other aids-related malignancies. Curr. HIV/AIDS Rep. 2004, 1, 5-11.
43. Beral, V.; Peterman, T.A.; Berkelman, R.L.; Jaffe, H.W. Kaposi’s sarcoma among persons with aids: A sexually transmitted infection? Lancet 1990, 335, 123-128.
44. Radkov, S.A.; Kellam, P.; Boshoff, C. The latent nuclear antigen of kaposi sarcoma-associated herpesvirus targets the retinoblastoma-e2f pathway and with the oncogene hras transforms primary rat cells. Nat. Med. 2000, 6, 1121-1127.
45. Chugh, P.; Matta, H.; Schamus, S.; Zachariah, S.; Kumar, A.; Richardson, J.A.; Smith, A.L.; Chaudhary, P.M. Constitutive nf-kappab activation, normal fas-induced apoptosis, and increased incidence of lymphoma in human herpes virus 8 k13 transgenic mice. Proc. Natl. Acad. Sci. USA 2005, 102, 12885-12890.
46. Sun, Q.; Zachariah, S.; Chaudhary, P.M. The human herpes virus 8-encoded viral flice-inhibitory protein induces cellular transformation via nf-kappab activation. J. Biol. Chem. 2003, 278, 52437-52445.
47. Wang, L.; Dittmer, D.P.; Tomlinson, C.C.; Fakhari, F.D.; Damania, B. Immortalization of primary endothelial cells by the k1 protein of kaposi’s sarcoma-associated herpesvirus. Cancer Res. 2006, 66, 3658-3666.
48. Staskus, K.A.; Zhong, W.; Gebhard, K.; Herndier, B.; Wang, H.; Renne, R.; Beneke, J.; Pudney, J.; Anderson, D.J.; Ganem, D., et al. Kaposi’s sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J. Virol. 1997, 71, 715-719.
49. Xie, J.; Pan, H.; Yoo, S.; Gao, S.J. Kaposi’s sarcoma-associated herpesvirus induction of ap-1 and interleukin 6 during primary infection mediated by multiple mitogen-activated protein kinase pathways. J. Virol. 2005, 79, 15027-15037.
50. Naranatt, P.P.; Krishnan, H.H.; Svojanovsky, S.R.; Bloomer, C.; Mathur, S.; Chandran, B. Host gene induction and transcriptional reprogramming in kaposi’s sarcoma-associated herpesvirus (kshv/hhv-8)-infected endothelial, fibroblast, and b cells: Insights into modulation events early during infection. Cancer Res. 2004, 64, 72-84.
51. Masood, R.; Cesarman, E.; Smith, D.L.; Gill, P.S.; Flore, O. Human herpesvirus-8-transformed endothelial cells have functionally activated vascular endothelial growth factor/vascular endothelial growth factor receptor. Am. J. Pathol. 2002, 160, 23-29.
52. Cerimele, F.; Curreli, F.; Ely, S.; Friedman-Kien, A.E.; Cesarman, E.; Flore, O. Kaposi’s sarcoma-associated herpesvirus can productively infect primary human keratinocytes and alter their growth properties. J. Virol. 2001, 75, 2435-2443.
53. Hong, G.K.; Gulley, M.L.; Feng, W.H.; Delecluse, H.J.; Holley-Guthrie, E.; Kenney, S.C. Epstein-barr virus lytic infection contributes to lymphoproliferative disease in a scid mouse model. J. Virol. 2005, 79, 13993-14003.
54. Martel-Renoir, D.; Grunewald, V.; Touitou, R.; Schwaab, G.; Joab, I. Qualitative analysis of the expression of epstein-barr virus lytic genes in nasopharyngeal carcinoma biopsies. J. Gen. Virol. 1995, 76, 1401-1408.
55. Munoz, N.; Bosch, F.X.; de Sanjose, S.; Herrero, R.; Castellsague, X.; Shah, K.V.; Snijders, P.J.; Meijer, C.J. International Agency for Research on Cancer Multicenter Cervical Cancer Study, G. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 2003, 348, 518-527.
56. Clifford, G.M.; Smith, J.S.; Plummer, M.; Munoz, N.; Franceschi, S. Human papillomavirus types in invasive cervical cancer worldwide: A meta-analysis. Br. J. Cancer 2003, 88, 63-73.
57. Chow, L.T.; Broker, T.R. Human papillomavirus infections: Warts or cancer? Cold Spring Harbor Perspect. Biol. 2013, 5, 10.1101/cshperspect.a012997.
58. Woodman, C.B.; Collins, S.I.; Young, L.S. The natural history of cervical hpv infection: Unresolved issues. Nat. Rev. Cancer 2007, 7, 11-22.
59. Zur Hausen, H. Papillomaviruses-To vaccination and beyond. Biochem. Biokhimiia 2008, 73, 498-503.
60. Ghittoni, R.; Accardi, R.; Hasan, U.; Gheit, T.; Sylla, B.; Tommasino, M. The biological properties of e6 and e7 oncoproteins from human papillomaviruses. Virus Genes 2010, 40, 1-13.
61. Becker, J.C.; Houben, R.; Ugurel, S.; Trefzer, U.; Pfohler, C.; Schrama, D. Mc polyomavirus is frequently present in merkel cell carcinoma of european patients. J. Investig. Dermatol. 2009, 129, 248-250.
62. Carter, J.J.; Paulson, K.G.; Wipf, G.C.; Miranda, D.; Madeleine, M.M.; Johnson, L.G.; Lemos, B.D.; Lee, S.; Warcola, A.H.; Iyer, J.G., et al. Association of merkel cell polyomavirus-specific antibodies with merkel cell carcinoma. J. Natl. Cancer Inst. 2009, 101, 1510-1522.
63. Duncavage, E.J.; Zehnbauer, B.A.; Pfeifer, J.D. Prevalence of merkel cell polyomavirus in merkel cell carcinoma. Mod. Pathol. 2009, 22, 516-521.
64. Agelli, M.; Clegg, L.X. Epidemiology of primary merkel cell carcinoma in the United States. J. Am. Acad. Dermatol. 2003, 49, 832-841.
65. Hodgson, N.C. Merkel cell carcinoma: Changing incidence trends. J. Surg. Oncol. 2005, 89, 1-4.
66. Kassem, A.; Schopflin, A.; Diaz, C.; Weyers, W.; Stickeler, E.; Werner, M.; Zur Hausen, A. Frequent detection of merkel cell polyomavirus in human merkel cell carcinomas and identification of a unique deletion in the vp1 gene. Cancer Res. 2008, 68, 5009-5013.
67. Kwun, H.J.; Guastafierro, A.; Shuda, M.; Meinke, G.; Bohm, A.; Moore, P.S.; Chang, Y. The minimum replication origin of merkel cell polyomavirus has a unique large t-antigen loading architecture and requires small t-antigen expression for optimal replication. J. Virol. 2009, 83, 12118-12128.
68. Moens, U.; van Ghelue, M.; Johannessen, M. Oncogenic potentials of the human polyomavirus regulatory proteins. Cell. Mol. Life Sci. 2007, 64, 1656-1678.
69. Shuda, M.; Arora, R.; Kwun, H.J.; Feng, H.; Sarid, R.; Fernandez-Figueras, M.T.; Tolstov, Y.; Gjoerup, O.; Mansukhani, M.M.; Swerdlow, S.H., et al. Human merkel cell polyomavirus infection i. Mcv t antigen expression in merkel cell carcinoma, lymphoid tissues and lymphoid tumors. Int. J. Cancer 2009, 125, 1243-1249.
70. Shuda, M.; Feng, H.; Kwun, H.J.; Rosen, S.T.; Gjoerup, O.; Moore, P.S.; Chang, Y. T antigen mutations are a human tumor-specific signature for merkel cell polyomavirus. Proc. Natl. Acad. Sci. USA 2008, 105, 16272-16277.
71. Houben, R.; Adam, C.; Baeurle, A.; Hesbacher, S.; Grimm, J.; Angermeyer, S.; Henzel, K.; Hauser, S.; Elling, R.; Brocker, E.B., et al. An intact retinoblastoma protein-binding site in merkel cell polyomavirus large t antigen is required for promoting growth of merkel cell carcinoma cells. Int. J. Cancer 2012, 130, 847-856.
72. Houben, R.; Shuda, M.; Weinkam, R.; Schrama, D.; Feng, H.; Chang, Y.; Moore, P.S.; Becker, J.C. Merkel cell polyomavirus-infected merkel cell carcinoma cells require expression of viral t antigens. J. Virol. 2010, 84, 7064-7072.
73. Shuda, M.; Kwun, H.J.; Feng, H.; Chang, Y.; Moore, P.S. Human merkel cell polyomavirus small t antigen is an oncoprotein targeting the 4e-bp1 translation regulator. J. Clin. Investig. 2011, 121, 3623-3634.
74. Kew, M.C. Epidemiology of chronic hepatitis b virus infection, hepatocellular carcinoma, and hepatitis b virus-induced hepatocellular carcinoma. Pathol.-Biol. 2010, 58, 273-277.
75. Tarocchi, M.; Polvani, S.; Marroncini, G.; Galli, A. Molecular mechanism of hepatitis b virusinduced hepatocarcinogenesis. World J. Gastroenterol. 2014, 20, 11630-11640.
76. Sung, W.K.; Zheng, H.; Li, S.; Chen, R.; Liu, X.; Li, Y.; Lee, N.P.; Lee, W.H.; Ariyaratne, P.N.; Tennakoon, C., et al. Genome-wide survey of recurrent hbv integration in hepatocellular carcinoma. Nat. Genet. 2012, 44, 765-769.
77. Wen, Y.; Golubkov, V.S.; Strongin, A.Y.; Jiang, W.; Reed, J.C. Interaction of hepatitis b viral oncoprotein with cellular target hbxip dysregulates centrosome dynamics and mitotic spindle formation. J. Biol. Chem. 2008, 283, 2793-2803.
78. Kim, C.M.; Koike, K.; Saito, I.; Miyamura, T.; Jay, G. Hbx gene of hepatitis b virus induces liver cancer in transgenic mice. Nature 1991, 351, 317-320.
79. Simmonds, P.; Bukh, J.; Combet, C.; Deleage, G.; Enomoto, N.; Feinstone, S.; Halfon, P.; Inchauspe, G.; Kuiken, C.; Maertens, G., et al. Consensus proposals for a unified system of nomenclature of hepatitis c virus genotypes. Hepatology 2005, 42, 962-973.
80. Tang, H.; Grise, H. Cellular and molecular biology of hcv infection and hepatitis. Clin. Sci. 2009, 117, 49-65.
81. Morgan, R.L.; Baack, B.; Smith, B.D.; Yartel, A.; Pitasi, M.; Falck-Ytter, Y. Eradication of hepatitis c virus infection and the development of hepatocellular carcinoma: A meta-analysis of observational studies. Ann. Intern. Med. 2013, 158, 329-337.
82. Moriya, K.; Fujie, H.; Shintani, Y.; Yotsuyanagi, H.; Tsutsumi, T.; Ishibashi, K.; Matsuura, Y.; Kimura, S.; Miyamura, T.; Koike, K. The core protein of hepatitis c virus induces hepatocellular carcinoma in transgenic mice. Nat. Med. 1998, 4, 1065-1067.
83. Moriya, K.; Yotsuyanagi, H.; Shintani, Y.; Fujie, H.; Ishibashi, K.; Matsuura, Y.; Miyamura, T.; Koike, K. Hepatitis c virus core protein induces hepatic steatosis in transgenic mice. J. Gen. Virol. 1997, 78 (Pt 7), 1527-1531.
84. Pei, Y.; Zhang, T.; Renault, V.; Zhang, X. An overview of hepatocellular carcinoma study by omics-based methods. Acta Biochim. Biophys. Sin. 2009, 41, 1-15.
85. Nunez, O.; Fernandez-Martinez, A.; Majano, P.L.; Apolinario, A.; Gomez-Gonzalo, M.; Benedicto, I.; Lopez-Cabrera, M.; Bosca, L.; Clemente, G.; Garcia-Monzon, C., et al. Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis c virus infection: Role of viral core and ns5a proteins. Gut 2004, 53, 1665-1672.
86. Murakami, A.; Ohigashi, H. Targeting nox, inos and cox-2 in inflammatory cells: Chemoprevention using food phytochemicals. Int. J. Cancer 2007, 121, 2357-2363.
87. Ohshima, H.; Tazawa, H.; Sylla, B.S.; Sawa, T. Prevention of human cancer by modulation of chronic inflammatory processes. Mutat. Res. 2005, 591, 110-122.
88. Fujinaga, H.; Tsutsumi, T.; Yotsuyanagi, H.; Moriya, K.; Koike, K. Hepatocarcinogenesis in hepatitis c: Hcv shrewdly exacerbates oxidative stress by modulating both production and scavenging of reactive oxygen species. Oncology 2011, 81 (Suppl. S1), 11-17.
89. Kannian, P.; Green, P.L. Human t lymphotropic virus type 1 (htlv-1): Molecular biology and oncogenesis. Viruses 2010, 2, 2037-2077.
90. Proietti, F.A.; Carneiro-Proietti, A.B.; Catalan-Soares, B.C.; Murphy, E.L. Global epidemiology of htlv-i infection and associated diseases. Oncogene 2005, 24, 6058-6068.
91. Grassmann, R.; Dengler, C.; Muller-Fleckenstein, I.; Fleckenstein, B.; McGuire, K.; Dokhelar, M.C.; Sodroski, J.G.; Haseltine, W.A. Transformation to continuous growth of primary human t lymphocytes by human t-cell leukemia virus type i x-region genes transduced by a herpesvirus saimiri vector. Proc. Natl. Acad. Sci. USA 1989, 86, 3351-3355.
92. Grassmann, R.; Berchtold, S.; Radant, I.; Alt, M.; Fleckenstein, B.; Sodroski, J.G.; Haseltine, W.A.; Ramstedt, U. Role of human t-cell leukemia virus type 1 x region proteins in immortalization of primary human lymphocytes in culture. J. Virol. 1992, 66, 4570-4575.
93. Akagi, T.; Shimotohno, K. Proliferative response of tax1-transduced primary human t cells to anti-cd3 antibody stimulation by an interleukin-2-independent pathway. J. Virol. 1993, 67, 1211-1217.
94. Hasegawa, H.; Sawa, H.; Lewis, M.J.; Orba, Y.; Sheehy, N.; Yamamoto, Y.; Ichinohe, T.; Tsunetsugu-Yokota, Y.; Katano, H.; Takahashi, H., et al. Thymus-derived leukemia-lymphoma in mice transgenic for the tax gene of human t-lymphotropic virus type i. Nat. Med. 2006, 12, 466-472.
95. Benvenisty, N.; Ornitz, D.M.; Bennett, G.L.; Sahagan, B.G.; Kuo, A.; Cardiff, R.D.; Leder, P. Brain tumours and lymphomas in transgenic mice that carry htlv-i ltr/c-myc and ig/tax genes. Oncogene 1992, 7, 2399-2405.
96. Azran, I.; Schavinsky-Khrapunsky, Y.; Aboud, M. Role of tax protein in human t-cell leukemia virus type-i leukemogenicity. Retrovirology 2004, 1, 20.
97. Li, X.H.; Gaynor, R.B. Mechanisms of nf-kappab activation by the htlv type 1 tax protein. AIDS Res. Hum. Retrovir. 2000, 16, 1583-1590.
98. Harhaj, E.W.; Harhaj, N.S.; Grant, C.; Mostoller, K.; Alefantis, T.; Sun, S.C.; Wigdahl, B. Human t cell leukemia virus type i tax activates cd40 gene expression via the nf-kappa b pathway. Virology 2005, 333, 145-158.
99. Mori, N.; Fujii, M.; Cheng, G.; Ikeda, S.; Yamasaki, Y.; Yamada, Y.; Tomonaga, M.; Yamamoto, N. Human t-cell leukemia virus type i tax protein induces the expression of anti-apoptotic gene bcl-xl in human t-cells through nuclear factor-kappab and c-amp responsive element binding protein pathways. Virus Genes 2001, 22, 279-287.
100. Hollstein, M.; Sidransky, D.; Vogelstein, B.; Harris, C.C. P53 mutations in human cancers. Science 1991, 253, 49-53.
101. Levine, A.J.; Momand, J.; Finlay, C.A. The p53 tumour suppressor gene. Nature 1991, 351, 453-456.
102. Khidr, L.; Chen, P.L. Rb, the conductor that orchestrates life, death and differentiation. Oncogene 2006, 25, 5210-5219.
103. Lee, J.M.; Bernstein, A. Apoptosis, cancer and the p53 tumour suppressor gene. Cancer Metastasis Rev. 1995, 14, 149-161.
104. Amundson, S.A.; Myers, T.G.; Fornace, A.J., Jr. Roles for p53 in growth arrest and apoptosis: Putting on the brakes after genotoxic stress. Oncogene 1998, 17, 3287-3299.
105. Scheffner, M.; Werness, B.A.; Huibregtse, J.M.; Levine, A.J.; Howley, P.M. The e6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990, 63, 1129-1136.
106. Scheffner, M.; Huibregtse, J.M.; Vierstra, R.D.; Howley, P.M. The hpv-16 e6 and e6-ap complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993, 75, 495-505.
107. Reznikoff, C.A.; Yeager, T.R.; Belair, C.D.; Savelieva, E.; Puthenveettil, J.A.; Stadler, W.M. Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 e6, but not e7, transformed human uroepithelial cells. Cancer Res. 1996, 56, 2886-2890.
108. Dyson, N.; Howley, P.M.; Munger, K.; Harlow, E. The human papilloma virus-16 e7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989, 243, 934-937.
109. Giam, C.Z.; Jeang, K.T. Htlv-1 tax and adult t-cell leukemia. Front. Biosci.: J. Virtual Libr. 2007, 12, 1496-1507.
110. Pise-Masison, C.A.; Brady, J.N. Setting the stage for transformation: Htlv-1 tax inhibition of p53 function. Front. Biosci. 2005, 10, 919-930.
111. Haller, K.; Wu, Y.; Derow, E.; Schmitt, I.; Jeang, K.T.; Grassmann, R. Physical interaction of human t-cell leukemia virus type 1 tax with cyclin-dependent kinase 4 stimulates the phosphorylation of retinoblastoma protein. Mol. Cell. Biol. 2002, 22, 3327-3338.
112. Suzuki, T.; Narita, T.; Uchida-Toita, M.; Yoshida, M. Down-regulation of the ink4 family of cyclin-dependent kinase inhibitors by tax protein of htlv-1 through two distinct mechanisms. Virology 1999, 259, 384-391.
113. Suzuki, T.; Kitao, S.; Matsushime, H.; Yoshida, M. Htlv-1 tax protein interacts with cyclindependent kinase inhibitor p16ink4a and counteracts its inhibitory activity towards cdk4. EMBO J. 1996, 15, 1607-1614.
114. Satou, Y.; Yasunaga, J.; Yoshida, M.; Matsuoka, M. Htlv-i basic leucine zipper factor gene mrna supports proliferation of adult t cell leukemia cells. Proc. Natl. Acad. Sci. USA 2006, 103, 720-725.
115. Cai, Q.L.; Knight, J.S.; Verma, S.C.; Zald, P.; Robertson, E.S. Ec5s ubiquitin complex is recruited by kshv latent antigen lana for degradation of the vhl and p53 tumor suppressors. PLoS Pathog. 2006, 2, e116.
116. Friborg, J., Jr.; Kong, W.; Hottiger, M.O.; Nabel, G.J. P53 inhibition by the lana protein of kshv protects against cell death. Nature 1999, 402, 889-894.
117. Si, H.; Robertson, E.S. Kaposi’s sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen induces chromosomal instability through inhibition of p53 function. J. Virol. 2006, 80, 697-709.
118. Spender, L.C.; Cannell, E.J.; Hollyoake, M.; Wensing, B.; Gawn, J.M.; Brimmell, M.; Packham, G.; Farrell, P.J. Control of cell cycle entry and apoptosis in b lymphocytes infected by epsteinbarr virus. J. Virol. 1999, 73, 4678-4688.
119. Mei, Y.P.; Zhou, J.M.; Wang, Y.; Huang, H.; Deng, R.; Feng, G.K.; Zeng, Y.X.; Zhu, X.F. Silencing of lmp1 induces cell cycle arrest and enhances chemosensitivity through inhibition of akt signaling pathway in ebv-positive nasopharyngeal carcinoma cells. Cell Cycle 2007, 6, 1379-1385.
120. Portis, T.; Longnecker, R. Epstein-barr virus (ebv) lmp2a mediates b-lymphocyte survival through constitutive activation of the ras/pi3k/akt pathway. Oncogene 2004, 23, 8619-8628.
121. Desbien, A.L.; Kappler, J.W.; Marrack, P. The epstein-barr virus bcl-2 homolog, bhrf1, blocks apoptosis by binding to a limited amount of bim. Proc. Natl. Acad. Sci. USA 2009, 106, 5663-5668.
122. Saggioro, D.; Silic-Benussi, M.; Biasiotto, R.; D’Agostino, D.M.; Ciminale, V. Control of cell death pathways by htlv-1 proteins. Front. Biosci. 2009, 14, 3338-3351.
123. Underbrink, M.P.; Howie, H.L.; Bedard, K.M.; Koop, J.I.; Galloway, D.A. E6 proteins from multiple human betapapillomavirus types degrade bak and protect keratinocytes from apoptosis after uvb irradiation. J. Virol. 2008, 82, 10408-10417.
124. Garnett, T.O.; Filippova, M.; Duerksen-Hughes, P.J. Accelerated degradation of fadd and procaspase 8 in cells expressing human papilloma virus 16 e6 impairs trail-mediated apoptosis. Cell Death Differ. 2006, 13, 1915-1926.
125. Yuan, H.; Fu, F.; Zhuo, J.; Wang, W.; Nishitani, J.; An, D.S.; Chen, I.S.; Liu, X. Human papillomavirus type 16 e6 and e7 oncoproteins upregulate c-iap2 gene expression and confer resistance to apoptosis. Oncogene 2005, 24, 5069-5078.
126. Filippova, M.; Parkhurst, L.; Duerksen-Hughes, P.J. The human papillomavirus 16 e6 protein binds to fas-associated death domain and protects cells from fas-triggered apoptosis. J. Biol. Chem. 2004, 279, 25729-25744.
127. Du, J.; Chen, G.G.; Vlantis, A.C.; Chan, P.K.; Tsang, R.K.; van Hasselt, C.A. Resistance to apoptosis of hpv 16-infected laryngeal cancer cells is associated with decreased bak and increased bcl-2 expression. Cancer Lett. 2004, 205, 81-88.
128. Becker, S.A.; Lee, T.H.; Butel, J.S.; Slagle, B.L. Hepatitis b virus x protein interferes with cellular DNA repair. J. Virol. 1998, 72, 266-272.
129. Aweya, J.J.; Tan, Y.J. Modulation of programmed cell death pathways by the hepatitis c virus. Front. Biosci. 2011, 16, 608-618.
130. Plug-DeMaggio, A.W.; Sundsvold, T.; Wurscher, M.A.; Koop, J.I.; Klingelhutz, A.J.; McDougall, J.K. Telomere erosion and chromosomal instability in cells expressing the hpv oncogene 16e6. Oncogene 2004, 23, 3561-3571.
131. Duensing, S.; Munger, K. The human papillomavirus type 16 e6 and e7 oncoproteins independently induce numerical and structural chromosome instability. Cancer Res. 2002, 62, 7075-7082.
132. Duensing, S.; Duensing, A.; Crum, C.P.; Munger, K. Human papillomavirus type 16 e7 oncoprotein-induced abnormal centrosome synthesis is an early event in the evolving malignant phenotype. Cancer Res. 2001, 61, 2356-2360.
133. Duensing, S.; Lee, L.Y.; Duensing, A.; Basile, J.; Piboonniyom, S.; Gonzalez, S.; Crum, C.P.; Munger, K. The human papillomavirus type 16 e6 and e7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle. Proc. Natl. Acad. Sci. USA 2000, 97, 10002-10007.
134. Chen, J.J. Genomic instability induced by human papillomavirus oncogenes. North Am. J. Med. Sci. 2010, 3, 43-47.
135. Bornkamm, G.W. Epstein-barr virus and its role in the pathogenesis of burkitt’s lymphoma: An unresolved issue. Semin. Cancer Biol. 2009, 19, 351-365.
136. Heath, E.; Begue-Pastor, N.; Chaganti, S.; Croom-Carter, D.; Shannon-Lowe, C.; Kube, D.; Feederle, R.; Delecluse, H.J.; Rickinson, A.B.; Bell, A.I. Epstein-barr virus infection of naive b cells in vitro frequently selects clones with mutated immunoglobulin genotypes: Implications for virus biology. PLoS Pathog. 2012, 8, e1002697.
137. Marriott, S.J.; Lemoine, F.J.; Jeang, K.T. Damaged DNA and miscounted chromosomes: Human t cell leukemia virus type i tax oncoprotein and genetic lesions in transformed cells. J. Biomed. Sci. 2002, 9, 292-298.
138. Lemoine, F.J.; Marriott, S.J. Genomic instability driven by the human t-cell leukemia virus type i (htlv-i) oncoprotein, tax. Oncogene 2002, 21, 7230-7234.
139. Chandhasin, C.; Ducu, R.I.; Berkovich, E.; Kastan, M.B.; Marriott, S.J. Human t-cell leukemia virus type 1 tax attenuates the atm-mediated cellular DNA damage response. J. Virol. 2008, 82, 6952-6961.
140. Kao, S.Y.; Lemoine, F.J.; Marriott, S.J. P53-independent induction of apoptosis by the htlv-i tax protein following uv irradiation. Virology 2001, 291, 292-298.
141. Jin, D.Y.; Spencer, F.; Jeang, K.T. Human t cell leukemia virus type 1 oncoprotein tax targets the human mitotic checkpoint protein mad1. Cell 1998, 93, 81-91.
142. Liu, B.; Hong, S.; Tang, Z.; Yu, H.; Giam, C.Z. Htlv-i tax directly binds the cdc20-associated anaphase-promoting complex and activates it ahead of schedule. Proc. Natl. Acad. Sci. USA 2005, 102, 63-68.
143. Cohen, S.B.; Graham, M.E.; Lovrecz, G.O.; Bache, N.; Robinson, P.J.; Reddel, R.R. Protein composition of catalytically active human telomerase from immortal cells. Science 2007, 315, 1850-1853.
144. Terrin, L.; dal Col, J.; Rampazzo, E.; Zancai, P.; Pedrotti, M.; Ammirabile, G.; Bergamin, S.; Rizzo, S.; Dolcetti, R.; de Rossi, A. Latent membrane protein 1 of epstein-barr virus activates the htert promoter and enhances telomerase activity in b lymphocytes. J. Virol. 2008, 82, 10175-10187.
145. Zhang, X.; Dong, N.; Zhang, H.; You, J.; Wang, H.; Ye, L. Effects of hepatitis b virus x protein on human telomerase reverse transcriptase expression and activity in hepatoma cells. J. Lab. Clin. Med. 2005, 145, 98-104.
146. Verma, S.C.; Borah, S.; Robertson, E.S. Latency-associated nuclear antigen of kaposi’s sarcoma-associated herpesvirus up-regulates transcription of human telomerase reverse transcriptase promoter through interaction with transcription factor sp1. J. Virol. 2004, 78, 10348-10359.
147. Gewin, L.; Myers, H.; Kiyono, T.; Galloway, D.A. Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 e6/e6-ap complex. Genes Dev. 2004, 18, 2269-2282.
148. Chen, X.; Kamranvar, S.A.; Masucci, M.G. Tumor viruses and replicative immortality-Avoiding the telomere hurdle. Semin. Cancer Biol. 2014, 26, 43-51.
149. Ohashi, M.; Sakurai, M.; Higuchi, M.; Mori, N.; Fukushi, M.; Oie, M.; Coffey, R.J.; Yoshiura, K.; Tanaka, Y.; Uchiyama, M., et al. Human t-cell leukemia virus type 1 tax oncoprotein induces and interacts with a multi-pdz domain protein, magi-3. Virology 2004, 320, 52-62.
150. Glaunsinger, B.A.; Lee, S.S.; Thomas, M.; Banks, L.; Javier, R. Interactions of the pdz-protein magi-1 with adenovirus e4-orf1 and high-risk papillomavirus e6 oncoproteins. Oncogene 2000, 19, 5270-5280.
151. Rousset, R.; Fabre, S.; Desbois, C.; Bantignies, F.; Jalinot, P. The c-terminus of the htlv-1 tax oncoprotein mediates interaction with the pdz domain of cellular proteins. Oncogene 1998, 16, 643-654.
152. Lee, S.S.; Weiss, R.S.; Javier, R.T. Binding of human virus oncoproteins to hdlg/sap97, a mammalian homolog of the drosophila discs large tumor suppressor protein. Proc. Natl. Acad. Sci. USA 1997, 94, 6670-6675.
153. Spanos, W.C.; Hoover, A.; Harris, G.F.; Wu, S.; Strand, G.L.; Anderson, M.E.; Klingelhutz, A.J.; Hendriks, W.; Bossler, A.D.; Lee, J.H. The pdz binding motif of human papillomavirus type 16 e6 induces ptpn13 loss, which allows anchorage-independent growth and synergizes with ras for invasive growth. J. Virol. 2008, 82, 2493-2500.
154. Spanos, W.C.; Geiger, J.; Anderson, M.E.; Harris, G.F.; Bossler, A.D.; Smith, R.B.; Klingelhutz, A.J.; Lee, J.H. Deletion of the pdz motif of hpv16 e6 preventing immortalization and anchorageindependent growth in human tonsil epithelial cells. Head Neck 2008, 30, 139-147.
155. Xie, L.; Yamamoto, B.; Haoudi, A.; Semmes, O.J.; Green, P.L. Pdz binding motif of htlv-1 tax promotes virus-mediated t-cell proliferation in vitro and persistence in vivo. Blood 2006, 107, 1980-1988.
156. Hirata, A.; Higuchi, M.; Niinuma, A.; Ohashi, M.; Fukushi, M.; Oie, M.; Akiyama, T.; Tanaka, Y.; Gejyo, F.; Fujii, M. Pdz domain-binding motif of human t-cell leukemia virus type 1 tax oncoprotein augments the transforming activity in a rat fibroblast cell line. Virology 2004, 318, 327-336.
157. Bartel, D.P. Micrornas: Genomics, biogenesis, mechanism, and function. Cell 2004, 116, 281-297.
158. Lewis, B.P.; Burge, C.B.; Bartel, D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microrna targets. Cell 2005, 120, 15-20.
159. Calin, G.A.; Croce, C.M. Microrna signatures in human cancers. Nat. Rev. Cancer 2006, 6, 857-866.
160. Lu, J.; Getz, G.; Miska, E.A.; Alvarez-Saavedra, E.; Lamb, J.; Peck, D.; Sweet-Cordero, A.; Ebert, B.L.; Mak, R.H.; Ferrando, A.A., et al. Microrna expression profiles classify human cancers. Nature 2005, 435, 834-838.
161. Cai, X.; Schafer, A.; Lu, S.; Bilello, J.P.; Desrosiers, R.C.; Edwards, R.; Raab-Traub, N.; Cullen, B.R. Epstein-barr virus micrornas are evolutionarily conserved and differentially expressed. PLoS Pathog. 2006, 2, e23.
162. Pfeffer, S.; Zavolan, M.; Grasser, F.A.; Chien, M.; Russo, J.J.; Ju, J.; John, B.; Enright, A.J.; Marks, D.; Sander, C., et al. Identification of virus-encoded micrornas. Science 2004, 304, 734-736.
163. Choy, E.Y.; Siu, K.L.; Kok, K.H.; Lung, R.W.; Tsang, C.M.; To, K.F.; Kwong, D.L.; Tsao, S.W.; Jin, D.Y. An epstein-barr virus-encoded microrna targets puma to promote host cell survival. J. Exp. Med. 2008, 205, 2551-2560.
164. Dolken, L.; Malterer, G.; Erhard, F.; Kothe, S.; Friedel, C.C.; Suffert, G.; Marcinowski, L.; Motsch, N.; Barth, S.; Beitzinger, M., et al. Systematic analysis of viral and cellular microrna targets in cells latently infected with human gamma-herpesviruses by risc immunoprecipitation assay. Cell Host Microbe 2010, 7, 324-334.
165. Marquitz, A.R.; Mathur, A.; Nam, C.S.; Raab-Traub, N. The epstein-barr virus bart micrornas target the pro-apoptotic protein bim. Virology 2011, 412, 392-400.
166. Marquitz, A.R.; Raab-Traub, N. The role of mirnas and ebv barts in npc. Semin. Cancer Biol. 2012, 22, 166-172.
167. Marquitz, A.R.; Mathur, A.; Shair, K.H.; Raab-Traub, N. Infection of epstein-barr virus in a gastric carcinoma cell line induces anchorage independence and global changes in gene expression. Proc. Natl. Acad. Sci. USA 2012, 109, 9593-9598.
168. Blattner, W.A. Human retroviruses: Their role in cancer. Proc. Assoc. Am. Phys. 1999, 111, 563-572.
169. Kim, H.H.; van den Heuvel, A.P.; Schmidt, J.W.; Ross, S.R. Novel common integration sites targeted by mouse mammary tumor virus insertion in mammary tumors have oncogenic activity. PLoS One 2011, 6, e27425.
170. Sourvinos, G.; Tsatsanis, C.; Spandidos, D.A. Mechanisms of retrovirus-induced oncogenesis. Folia Biol. 2000, 46, 226-232.
171. Chimal-Ramirez, G.K.; Espinoza-Sanchez, N.A.; Fuentes-Panana, E.M. Protumor activities of the immune response: Insights in the mechanisms of immunological shift, oncotraining, and oncopromotion. J. Oncol. 2013, 2013, 835956.
172. Elinav, E.; Nowarski, R.; Thaiss, C.A.; Hu, B.; Jin, C.; Flavell, R.A. Inflammation-induced cancer: Crosstalk between tumours, immune cells and microorganisms. Nat. Rev. Cancer 2013, 13, 759-771.
173. Schistosomes, Liver Flukes and Helicobacter Pylori. Iarc working group on the evaluation of carcinogenic risks to humans. Lyon, 7-14 June 1994. IARC Monogr. Eval. Carcinog. Risks Hum. 1994, 61, 1-241.
174. Fuentes-Panana, E.; Camorlinga-Ponce, M.; Maldonado-Bernal, C. Infection, inflammation and gastric cancer. Salud Publica Mex. 2009, 51, 427-433.
175. Kusters, J.G.; van Vliet, A.H.; Kuipers, E.J. Pathogenesis of Helicobacter pylori infection. Clin. Microbiol. Rev. 2006, 19, 449-490.
176. Xu, J.; Yin, Z.; Cao, S.; Gao, W.; Liu, L.; Yin, Y.; Liu, P.; Shu, Y. Systematic review and meta-analysis on the association between il-1b polymorphisms and cancer risk. PLoS One 2013, 8, e63654.
177. Xue, H.; Lin, B.; Ni, P.; Xu, H.; Huang, G. Interleukin-1b and interleukin-1 rn polymorphisms and gastric carcinoma risk: A meta-analysis. J. Gastroenterol. Hepatol. 2010, 25, 1604-1617.
178. Crusius, J.B.; Canzian, F.; Capella, G.; Pena, A.S.; Pera, G.; Sala, N.; Agudo, A.; Rico, F.; Del Giudice, G.; Palli, D., et al. Cytokine gene polymorphisms and the risk of adenocarcinoma of the stomach in the european prospective investigation into cancer and nutrition (epic-eurgast). Ann. Oncol. 2008, 19, 1894-1902.
179. Cheng, D.; Hao, Y.; Zhou, W.; Ma, Y. Positive association between interleukin-8-251a>t polymorphism and susceptibility to gastric carcinogenesis: A meta-analysis. Cancer Cell Int. 2013, 13, 100.
180. Poli, G. Pathogenesis of liver fibrosis: Role of oxidative stress. Mol. Asp. Med. 2000, 21, 49-98.
181. Cardenas-Mondragon, M.G.; Carreon-Talavera, R.; Camorlinga-Ponce, M.; Gomez-Delgado, A.; Torres, J.; Fuentes-Panana, E.M. Epstein barr virus and helicobacter pylori co-infection are positively associated with severe gastritis in pediatric patients. PLoS One 2013, 8, e62850.
182. Cárdenas-Mondragón, M.; Carreón-Talavera, R.; Flores-Luna, L.; Camorlinga-Ponce, M.; Gómez-Delgado, A.; Torres, J.; Fuentes-Pananá, E. Epstein barr virus reactivation is an important trigger of gastric inflammation and progression to intestinal type gastric cancer. In Proceedings of the Epstein Barr Virus 50th Anniversary Conference, Keble College, Oxford, UK, 23-25 March, 2014.
183. Bernstein, W.B.; Little, R.F.; Wilson, W.H.; Yarchoan, R. Acquired immunodeficiency syndrome-related malignancies in the era of highly active antiretroviral therapy. Int. J. Hematol. 2006, 84, 3-11.
184. Young, L.S.; Murray, P.G. Epstein-barr virus and oncogenesis: From latent genes to tumours. Oncogene 2003, 22, 5108-5121.
185. Young, L.; Alfieri, C.; Hennessy, K.; Evans, H.; O’Hara, C.; Anderson, K.C.; Ritz, J.; Shapiro, R.S.; Rickinson, A.; Kieff, E., et al. Expression of epstein-barr virus transformation-associated genes in tissues of patients with ebv lymphoproliferative disease. N. Engl. J. Med. 1989, 321, 1080-1085.
186. Nourse, J.P.; Jones, K.; Gandhi, M.K. Epstein-barr virus-related post-transplant lymphoproliferative disorders: Pathogenetic insights for targeted therapy. Am. J. Transplant. 2011, 11, 888-895.
187. Gandhi, M.K.; Wilkie, G.M.; Dua, U.; Mollee, P.N.; Grimmett, K.; Williams, T.; Whitaker, N.; Gill, D.; Crawford, D.H. Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders. Am. J. Transplant. 2007, 7, 1293-1299.
188. Haque, T.; Wilkie, G.M.; Jones, M.M.; Higgins, C.D.; Urquhart, G.; Wingate, P.; Burns, D.; McAulay, K.; Turner, M.; Bellamy, C., et al. Allogeneic cytotoxic t-cell therapy for ebv-positive posttransplantation lymphoproliferative disease: Results of a phase 2 multicenter clinical trial. Blood 2007, 110, 1123-1131.
189. Michaelis, M.; Doerr, H.W.; Cinatl, J. The story of human cytomegalovirus and cancer: Increasing evidence and open questions. Neoplasia 2009, 11, 1-9.
190. Boldogh, I.; Huang, E.S.; Rady, P.; Arany, I.; Tyring, S.; Albrecht, T. Alteration in the coding potential and expression of h-ras in human cytomegalovirus-transformed cells. Intervirology 1994, 37, 321-329.
191. Geder, K.M.; Lausch, R.; O’Neill, F.; Rapp, F. Oncogenic transformation of human embryo lung cells by human cytomegalovirus. Science 1976, 192, 1134-1137.
192. Geder, L.; Kreider, J.; Rapp, F. Human cells transformed in vitro by human cytomegalovirus: Tumorigenicity in athymic nude mice. J. Natl. Cancer Inst. 1977, 58, 1003-1009.
193. Geder, L.; Laychock, A.M.; Gorodecki, J.; Rapp, F. Alterations in biological properties of different lines of cytomegalorivus-transformed human embryo lung cells following in vitro cultivation. IARC Sci. Publ. 1978, 24, 591-601.
194. Cinatl, J.; Scholz, M.; Kotchetkov, R.; Vogel, J.U.; Doerr, H.W. Molecular mechanisms of the modulatory effects of hcmv infection in tumor cell biology. Trends Mol. Med. 2004, 10, 19-23.
195. Scheurer, M.E.; Bondy, M.L.; Aldape, K.D.; Albrecht, T.; El-Zein, R. Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol. 2008, 116, 79-86.
196. Cobbs, C.S.; Soroceanu, L.; Denham, S.; Zhang, W.; Kraus, M.H. Modulation of oncogenic phenotype in human glioma cells by cytomegalovirus ie1-mediated mitogenicity. Cancer Res. 2008, 68, 724-730.
197. Maussang, D.; Verzijl, D.; van Walsum, M.; Leurs, R.; Holl, J.; Pleskoff, O.; Michel, D.; van Dongen, G.A.; Smit, M.J. Human cytomegalovirus-encoded chemokine receptor us28 promotes tumorigenesis. Proc. Natl. Acad. Sci. USA 2006, 103, 13068-13073.
198. Vallat, L.; Benhamou, Y.; Gutierrez, M.; Ghillani, P.; Hercher, C.; Thibault, V.; Charlotte, F.; Piette, J.C.; Poynard, T.; Merle-Beral, H., et al. Clonal b cell populations in the blood and liver of patients with chronic hepatitis c virus infection. Arthritis Rheum. 2004, 50, 3668-3678.
199. Quinn, E.R.; Chan, C.H.; Hadlock, K.G.; Foung, S.K.; Flint, M.; Levy, S. The b-cell receptor of a hepatitis c virus (hcv)-associated non-hodgkin lymphoma binds the viral e2 envelope protein, implicating hcv in lymphomagenesis. Blood 2001, 98, 3745-3749.
200. Chan, C.H.; Hadlock, K.G.; Foung, S.K.; Levy, S. V(h)1-69 gene is preferentially used by hepatitis c virus-associated b cell lymphomas and by normal b cells responding to the e2 viral antigen. Blood 2001, 97, 1023-1026.
201. Hermine, O.; Lefrere, F.; Bronowicki, J.P.; Mariette, X.; Jondeau, K.; Eclache-Saudreau, V.; Delmas, B.; Valensi, F.; Cacoub, P.; Brechot, C., et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis c virus infection. N. Engl. J. Med. 2002, 347, 89-94.
202. Zullo, A.; Hassan, C.; Cristofari, F.; Andriani, A.; de Francesco, V.; Ierardi, E.; Tomao, S.; Stolte, M.; Morini, S.; Vaira, D. Effects of helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin. Gastroenterol. Hepatol. 2010, 8, 105-110.
203. Skinner, G.R. Transformation of primary hamster embryo fibroblasts by type 2 simplex virus: Evidence for a “hit and run” mechanism. Br. J. Exp. Pathol. 1976, 57, 361-376.
204. Birdwell, C.E.; Queen, K.J.; Kilgore, P.C.; Rollyson, P.; Trutschl, M.; Cvek, U.; Scott, R.S. Genome-wide DNA methylation as an epigenetic consequence of epstein-barr virus infection of immortalized keratinocytes. J. Virol. 2014, 88, 11442-11458.
205. Burns, M.B.; Temiz, N.A.; Harris, R.S. Evidence for apobec3b mutagenesis in multiple human cancers. Nat. Genet. 2013, 45, 977-983.